Novel anti-CD33 immunoconjugate demonstrating in vitro and in vivo activity against human acute myeloid leukemia (AML) cells.

被引：0
|
作者：
Hebib, Nadia C.
Larochelle, Fannie
Lutz, Bob
Lambert, John
Blattler, Walter
Roy, Denis Claude
机构：
[1] Hop Maisonneuve Rosemont Res Ctr, Montreal, PQ, Canada
[2] ImmunoGen Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5558
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
    Mulford, DA
    Pandit-Taskar, N
    McDevitt, MR
    Finn, RD
    Weiss, MA
    Apostolidis, C
    Morgenstern, A
    Divgi, CR
    Larson, SM
    Scheinberg, DA
    Jurcic, JG
    BLOOD, 2004, 104 (11) : 496A - 496A
  • [32] In vitro comparison of chemosensitivity with immunosensitivity in human acute myeloid leukemia cells.
    Ozdemir, Oner
    Savasan, Sureyya
    CLINICAL IMMUNOLOGY, 2006, 119 : S92 - S92
  • [33] Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models
    Portwood, Scott
    Puchalski, Robert A.
    Walker, Russell M.
    Wang, Eunice S.
    BLOOD, 2016, 128 (22)
  • [34] Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195
    E Feldman
    M Kalaycio
    G Weiner
    S Frankel
    P Schulman
    L Schwartzberg
    J Jurcic
    E Velez-Garcia
    K Seiter
    D Scheinberg
    D Levitt
    N Wedel
    Leukemia, 2003, 17 : 314 - 318
  • [35] Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
    Hamann, PR
    Hinman, LM
    Hollander, I
    Beyer, CF
    Lindh, D
    Holcomb, R
    Hallett, W
    Tsou, HR
    Upeslacis, J
    Shochat, D
    Mountain, A
    Flowers, DA
    Bernstein, I
    BIOCONJUGATE CHEMISTRY, 2002, 13 (01) : 47 - 58
  • [36] ANTI-CD33 ACTINIUM-225 TARGETED RADIOIMMUNOTHERAPY ENHANCES THE BIOLOGIC ACTIVITY OF ANTI-CD47 ANTIBODY IMMUNOTHERAPY IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
    Pachhal, Sagarika
    Greer, Emily
    Hwang, Jesse
    Liang, Qing
    Chen, Mary
    Geoghegan, Eileen
    Kotanides, Helen
    Ludwig, Dale
    Beckford, Denis
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A620 - A620
  • [37] Comparison of viral vectors for transduction of primary human acute myeloid leukemia (AML) cells.
    Barlett, AL
    Marangolo, M
    Bailey, C
    Ginn, SL
    Bendall, LJ
    Bradstock, KF
    Rasko, J
    Gottlieb, DJ
    BLOOD, 2002, 100 (11) : 489B - 490B
  • [38] Expression of c-kit receptor CD 117 in acute myeloid leukemia (AML) cells.
    Threja, R
    Venugopal, P
    George, S
    Coon, J
    BLOOD, 2002, 100 (11) : 255B - 255B
  • [39] EFFECT OF MULTIPOTENT MESENCHYMAL STROMA CELLS (MSC) ON ACUTE MYELOID LEUKEMIA (AML) CELLS IN VITRO AND IN VIVO
    Schelker, Roland C.
    Mueller, Gunnar
    Hart, Christina
    Klatt, Sabine
    Herr, Wolfgang
    Grassinger, Jochen
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (09) : S94 - S94
  • [40] Anti-CD33 mAb enhances the cytotoxic effect of cytosine arabinoside (Ara-C) and idarubicin (IDA) on acute myeloid leukemia (AML) cells through similarities in their signaling pathways.
    Balaian, L
    Ball, ED
    BLOOD, 2003, 102 (11) : 871A - 872A
12345